Evidence map›Paper›PMID 29386045›Full record

ReviewStem cell research & therapy2018

Mesenchymal stem cell-based therapy for radiation-induced lung injury.

Tiankai Xu, Yuyu Zhang, Pengyu Chang, Shouliang Gong, Lihong Shao, Lihua Dong

Open access · goldAbstract readReview
In one paragraph

Review in Stem cell research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. [Mefloquine HCl promotes DNA repair and alleviates radiation-induced lung epithelial cell injury].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. [Normal mouse serum alleviates radiation pneumonitis in mice by inhibiting the focal adhesion signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tiankai XuDepartment of Radiation Oncology, The First Bethune Hospital of Jilin University, Changchun, Jilin, 130021, China.
Yuyu ZhangDepartment of Radiation Oncology, The First Bethune Hospital of Jilin University, Changchun, Jilin, 130021, China.
Pengyu ChangDepartment of Radiation Oncology, The First Bethune Hospital of Jilin University, Changchun, Jilin, 130021, China.
Shouliang GongDepartment of Radiation Oncology, The First Bethune Hospital of Jilin University, Changchun, Jilin, 130021, China.
Lihong ShaoDepartment of Radiation Oncology, The First Bethune Hospital of Jilin University, Changchun, Jilin, 130021, China. 326730262@qq.com.
Lihua DongDepartment of Radiation Oncology, The First Bethune Hospital of Jilin University, Changchun, Jilin, 130021, China. drlhdong@163.com.
First Bethune Hospital of Jilin University · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since radiotherapy is widely used in managing thoracic tumors, physicians have begun to realize that radiation-induced lung injury (RILI) seriously limits the effects of radiotherapy. Unfortunately, there are still no effective methods for controlling RILI. Over the last few decades numerous studies have reported the beneficial effects of mesenchymal stem cells (MSCs) on tissue repair and regeneration. MSCs can not only differentiate into lung alveolar epithelial cells and secrete anti-inflammatory factors, but they also deliver some vehicles for gene therapy in repairing the injured lung, which provides new ideas for managing RILI. Thus, many scientists have attempted to manage RILI using MSC-based therapy. However, as a novel therapy MSCs still face various limitations. Herein, we shed light on the current understanding of MSC-based therapy for RILI, including the feasibility, molecular mechanisms, animal studies, and clinical research of MSC-based therapy for RILI. We also present an overview of RILI and MSCs.

Indexed as

Mesenchymal Stem Cell TransplantationAlveolar Epithelial CellsAnimalsCell- and Tissue-Based TherapyHumansLung InjuryLung NeoplasmsMesenchymal Stem CellsMiceRadiation InjuriesRadiotherapyRatsRegenerationMesenchymal stem cells (MSCs)Radiation-induced lung injury (RILI)Stem cell therapy

Identifiers

PMID29386045
PMCPMC5793340
OpenAlexW2796390791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.